In a recent transaction, Barbara J. Desoer, a director at DaVita Inc . (NYSE:DVA), sold 5,030 shares of the company's common stock. The sale was executed at an average price of $138.81 per share, totaling approximately $698,214.
The shares were sold on May 10, 2024, and the transaction was reported in a Form 4 filing with the Securities and Exchange Commission. According to the details provided, the price range for the shares sold by Desoer was between $138.10 and $139.55. Following the sale, Desoer still owns a total of 10,954 shares in DaVita Inc., indicating continued investment in the company.
DaVita Inc., headquartered in Denver, Colorado, operates in the healthcare sector, providing a variety of health and allied services. The company has been a significant player in the industry, and its stock performance is closely watched by investors.
The transaction by Desoer is part of the regular financial disclosures required by company insiders, providing transparency to the market and allowing shareholders to stay informed about executive-level transactions in the company's stock.
InvestingPro Insights
DaVita Inc. (NYSE:DVA) has been making waves in the healthcare sector with its robust financial performance and strategic market positioning. A snapshot of the company's financial health, as per InvestingPro data, reveals a market capitalization of $11.98 billion, underscoring its substantial presence in the industry. The company's Price/Earnings (P/E) ratio stands at an attractive 15.11, which, when adjusted for the last twelve months as of Q1 2024, is slightly lower at 14.74. This suggests that DaVita's earnings are strong relative to its share price, offering potential value to investors.
Investors looking for growth opportunities might be intrigued by DaVita's PEG (Price/Earnings to Growth) ratio of 0.24 for the last twelve months as of Q1 2024, signaling that the stock could be undervalued based on its earnings growth. Moreover, DaVita has demonstrated a solid revenue growth of 5.77% over the same period, reflecting the company's ability to expand its financial top line in a competitive healthcare market.
Two InvestingPro Tips worth noting for DaVita include its perfect Piotroski Score of 9, indicating high financial strength, and the fact that management has been aggressively buying back shares, a sign of confidence in the company's future prospects. These insights, coupled with the company's status as a prominent player in the Healthcare Providers & Services industry, could be particularly relevant for investors considering the recent insider transaction.
For those seeking more in-depth analysis, InvestingPro offers a wealth of additional tips—12 for DaVita Inc., to be precise. These can provide a more comprehensive understanding of the company's performance and outlook. Readers interested in exploring these tips further may take advantage of a special offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.